Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Evozyne is a generative AI company that focuses on therapeutic discovery and drug development.
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing radiopharmaceuticals.
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer.
Tricida operates in the healthcare industry focusing on pharmaceutical business.
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.
MiroBio is Harnessing the natural control mechanisms of the immune system.
Frontera Therapeutics is an AAV gene therapy company that focuses on rAAV therapies for the global market.
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia.
OrbiMed has invested in 288 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.
Among tracked funding rounds, ACELYRIN received $300.0M in a Series C round. OrbiMed's total known invested capital is $31.2B.
OrbiMed's average investment size is $108.2M across its portfolio of 288 companies.
Recent OrbiMed portfolio additions include Forward Therapeutics, Rampart Bioscience, Harpoon Therapeutics, Minervax, Synlogic. These companies were founded in 2020 or later.